Trial Profile
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' HPV-16/18 L1 AS04 Vaccine When Administered According to Alternative 2-dose Schedules in 9 - 14 Year Old Females
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Oct 2023
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
- Indications Cervical cancer; Human papillomavirus infections
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline; GSK
- 03 Feb 2019 Results published in the Journal of Infectious Diseases
- 03 Feb 2016 Primary endpoint has been met. (Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations (by ELISA).), as per an article published in the Journal of Infectious Diseases.
- 03 Feb 2016 Primary endpoint has been met. (Number of Subjects Seroconverted for Anti- Human Papilloma Virus 16 (Anti-HPV-16) and Anti-Human Papilloma Virus 18 (Anti-HPV-18) Antibodies), as per an article published in the Journal of Infectious Diseases